{
    "Trade/Device Name(s)": [
        "Lumipulse G CA19-9-N",
        "Lumipulse G CA19-9-N Immunoreaction Cartridges"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K200997",
    "Predicate Device Reference 510(k) Number(s)": [
        "K191973"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NIG"
    ],
    "Summary Letter Date": "May 14, 2020",
    "Summary Letter Received Date": "April 16, 2020",
    "Submission Date": "April 15, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA 19-9"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Sodium heparin tube",
        "Lithium heparin tube",
        "Dipotassium EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LUMIPULSE G System",
        "LUMIPULSE G1200 System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent Enzyme Immunoassay (CLEIA)",
        "Immunoassay"
    ],
    "Methodologies": [
        "Chemiluminescent immunoassay",
        "Two-step immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Lumipulse G CA19-9-N assay, a CLEIA method for quantitative measurement of CA 19-9 in serum or plasma to aid in managing exocrine pancreatic cancer patients.",
    "Indications for Use Summary": "Aid in management of patients with diagnosed exocrine pancreatic cancer with detectable CA 19-9; not for cancer screening or diagnosis; serial testing used in conjunction with other clinical methods.",
    "fda_folder": "Immunology"
}